Literature DB >> 1951880

Experience with 998 cutaneous melanomas of the head and neck over 30 years.

C J O'Brien1, A S Coates, K Petersen-Schaefer, K Shannon, J F Thompson, G W Milton, W H McCarthy.   

Abstract

Between 1960 and 1990, a total of 998 patients were treated at the Sydney Melanoma Unit for cutaneous melanoma of the head and neck. There were 595 male and 403 female patients, with a median age of 53 years. The most common primary lesion site was the face (47%), followed by the neck (29%), scalp (14%), and ear (10%). Histologic types were as follows: superficial spreading 30%, nodular melanoma 28%, lentigo maligna melanoma 16%, and other 26%. All patients underwent surgical treatment. Primary closure of wounds was achieved in 52% of patients, and excision margins were 2 cm or less in 45%. A total of 152 patients had therapeutic neck dissections, and 234 had elective neck dissections. The overall local recurrence rate was 13%, and this was significantly influenced by increasing tumor thickness and Clark level. The recurrence rate in the neck after neck dissection was 24%, and the rate of parotid recurrences was 14%. Melanoma-specific survival was 77% at 5 years and 66% at 10 years for the entire group. By univariate analysis, survival varied significantly with age, tumor thickness, ulceration, anatomic sub-site, histologically positive nodes, and the presence of distant metastases. A diagnosis of lentigo maligna melanoma and elective lymph node dissection both appeared to improve survival. With multivariate analysis, all of these factors remained significant prognostic factors except elective node dissection, which lost its beneficial influence.

Entities:  

Mesh:

Year:  1991        PMID: 1951880     DOI: 10.1016/0002-9610(91)90138-4

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  17 in total

1.  The contralateral sentinel node.

Authors:  Ian K Komenaka; Eric T Nguyen; Gail DeRaffele; Josephine Mitcham; Karl S Hurst-Wicker; Howard L Kaufman
Journal:  Can J Surg       Date:  2005-10       Impact factor: 2.089

Review 2.  Melanoma of the head and neck.

Authors:  Terry A Day; Joshua D Hornig; Anand K Sharma; Frank Brescia; M Boyd Gillespie; Deanne Lathers
Journal:  Curr Treat Options Oncol       Date:  2005-01

3.  Mohs Micrographic Surgery Using MART-1 Immunostain in the Treatment of Invasive Melanoma and Melanoma In Situ.

Authors:  Sheila M Valentín-Nogueras; David G Brodland; John A Zitelli; Lorena González-Sepúlveda; Cruz M Nazario
Journal:  Dermatol Surg       Date:  2016-06       Impact factor: 3.398

4.  Tumor location predicts survival in cutaneous head and neck melanoma.

Authors:  Warren H Tseng; Steve R Martinez
Journal:  J Surg Res       Date:  2010-11-10       Impact factor: 2.192

5.  Ear melanoma: influence of perichondrium involvement in evaluating surgical strategy.

Authors:  L Sartore; G Giatsidis; F Reho; G Tanzillo; L Campana; R Salmaso
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-11-12       Impact factor: 2.503

6.  Neck dissection for cutaneous malignant melanoma.

Authors:  C J O'Brien; M P Gianoutsos; M J Morgan
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

7.  The prognostic importance of scalp location in primary head and neck melanoma.

Authors:  Junko Ozao-Choy; Daniel W Nelson; Jason Hiles; Stacey Stern; Jeong Lim Yoon; Myung Shin Sim; Mark B Faries
Journal:  J Surg Oncol       Date:  2017-05-22       Impact factor: 3.454

8.  Sentinel Lymph Node Biopsy for Cutaneous Head and Neck Melanoma: Mapping the Parotid Gland.

Authors:  Antonio I Picon; Daniel G Coit; Ashok R Shaha; Mary S Brady; Jay O Boyle; Bhuvanesh B Singh; Richard J Wong; Klaus J Busam; Jatin P Shah; Dennis H Kraus
Journal:  Ann Surg Oncol       Date:  2006-05-23       Impact factor: 5.344

9.  Fluorescently labeled therapeutic antibodies for detection of microscopic melanoma.

Authors:  Kristine E Day; Lauren N Beck; Nicholas L Deep; Joy Kovar; Kurt R Zinn; Eben L Rosenthal
Journal:  Laryngoscope       Date:  2013-04-24       Impact factor: 3.325

Review 10.  [Malignant head and neck melanoma: Part 2: Therapy].

Authors:  C Pföhler; T Vogt; C S L Müller
Journal:  HNO       Date:  2015-08       Impact factor: 1.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.